On April 1, 2016 BioWa, Inc. ("BioWa") reported that it was relocating its office from La Jolla, California to Princeton, New Jersey, and appointment of Mr. Takeshi Masuda, as the President and CEO for the next stage of corporate development (Press release, Kyowa Hakko Kirin, APR 1, 2016, View Source [SID:1234510289]).

Mr. Masuda has also served as President of Kyowa Kirin USA Holdings, Inc. the holding company of Kyowa Hakko Kirin’s US pharmaceutical subsidiaries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioWa develops partnerships with pharmaceutical companies and biotechs through the licensing of proprietary therapeutic antibody technologies POTELLIGENT and COMPLEGENT. These technologies were developed by Kyowa Hakko Kirin, Co. Ltd. and BioWa will be continuing a role as the exclusive worldwide licensor of those technologies after relocation to Princeton.